Literature DB >> 10448418

Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.

Q Chen1, A H Andersen, Z Zhang, A Ovadia, W A Cass, D M Gash, M J Avison.   

Abstract

Functional MRI (fMRI) was used to study striatal sensitivity to levodopa in hemiparkinsonian rhesus monkeys. Responses consistent with increased neuronal activity were seen in areas whose normal dopaminergic input from the substantia nigra pars compacta had been ablated by MPTP. Sites of increased activity following levodopa included the lateral putamen, the ventral region of the caudate head, septal areas, and midlateral amygdala in the MPTP-lesioned hemisphere. Increased activity was also observed in the same areas in the nonlesioned hemisphere, but was less pronounced in spatial extent and magnitude, suggesting either subclinical contralateral damage and/or functional adaptations in the contralateral dopamine systems. The increases in neuronal activity following levodopa treatment were temporally correlated with increases in striatal dopamine levels. Chronic levodopa treatment reduced behavioral responsiveness to levodopa and abolished the fMRI response. These results suggest that fMRI can detect changes in dopamine receptor-mediated neuronal sensitivity to dopaminergic agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448418     DOI: 10.1006/exnr.1999.7089

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

1.  Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.

Authors:  Liming Luan; Feng Ding; Yi Ai; Anders Andersen; Peter Hardy; Eric Forman; Greg A Gerhardt; Don M Gash; Richard Grondin; Zhiming Zhang
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

2.  Levodopa changes brain motor network function during ankle movements in Parkinson's disease.

Authors:  Petra Schwingenschuh; Petra Katschnig; Margit Jehna; Mariella Koegl-Wallner; Stephan Seiler; Karoline Wenzel; Stefan Ropele; Christian Langkammer; Thomas Gattringer; Martin Svehlík; Erwin Ott; Franz Fazekas; Reinhold Schmidt; Christian Enzinger
Journal:  J Neural Transm (Vienna)       Date:  2012-09-19       Impact factor: 3.575

Review 3.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

4.  Improved methods for electroacupuncture and electromyographic recordings in normal and parkinsonian rhesus monkeys.

Authors:  Feng Zhao; Xiaotong Fan; Richard Grondin; Ramsey Edwards; Eric Forman; Jennifer Moorehead; Greg Gerhardt; Xiaomin Wang; Zhiming Zhang
Journal:  J Neurosci Methods       Date:  2010-07-21       Impact factor: 2.390

5.  In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.

Authors:  Rosario Sánchez-Pernaute; Bruce G Jenkins; Ji-Kyung Choi; Yin-Ching Iris Chen; Ole Isacson
Journal:  Neurobiol Dis       Date:  2007-05-18       Impact factor: 5.996

6.  Distributed neural actions of anti-parkinsonian therapies as revealed by PET.

Authors:  I K Goerendt; A D Lawrence; M A Mehta; J S Stern; P Odin; D J Brooks
Journal:  J Neural Transm (Vienna)       Date:  2005-07-29       Impact factor: 3.575

7.  Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

Authors:  Bruce G Jenkins; Rosario Sanchez-Pernaute; Anna-Liisa Brownell; Yin-Ching Iris Chen; Ole Isacson
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.709

8.  Validations of apomorphine-induced BOLD activation correlations in hemiparkinsonian rhesus macaques.

Authors:  J E Quintero; Yi Ai; A H Andersen; P Hardy; R Grondin; Z Guduru; D M Gash; G A Gerhardt; Z Zhang
Journal:  Neuroimage Clin       Date:  2019-02-18       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.